Anxiety and depressive symptoms measured by the hospital anxiety and depression scale as predictors of time to recurrence in localized cutaneous melanoma

Acta Oncologica

Volumn 43, Issue 2, 2004, Pages 161-168

  Bergenmar, Mia ^a   Nilsson, Bo ^a   Hansson, Johan ^a   Brandberg, Yvonne ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGE; AGED; ANXIETY DISORDER; ARTICLE; CANCER DIAGNOSIS; CANCER GRADING; CANCER LOCALIZATION; CANCER PATIENT; CANCER RECURRENCE; CANCER SURVIVAL; CONTROLLED STUDY; DEPRESSION; DISEASE ASSOCIATION; FEMALE; HISTOPATHOLOGY; HOSPITAL ANXIETY AND DEPRESSION SCALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MELANOMA; MITOSIS INDEX; OUTCOMES RESEARCH; PRIORITY JOURNAL; PROGNOSIS; RATING SCALE; SKIN CARCINOMA;

AGE FACTORS; ANXIETY; DEPRESSION; FEMALE; HUMANS; MALE; MELANOMA; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PERSONALITY INVENTORY; PROGNOSIS; SEX FACTORS; SICKNESS IMPACT PROFILE; SKIN NEOPLASMS;

EID: 1842779067     PISSN: 0284186X     EISSN: None     Source Type: Journal    
DOI: 10.1080/02841860310021518     Document Type: Article

References (28)

1. Balch CM, Soong S-J, Gershenwald JE, et al. Prognostic factors analysis of 17 600 melanoma patients: Validation of the American Joint Committee on Cancer Melanoma Staging System. J Clin Oncol 2001; 19: 3622-34.
2. Måsbäck A, Olsson H, Westerdahl J, Ingvar C, Jonsson N. Prognostic factors in invasive cutaneous malignant melanoma: a population based study and review. Melanoma Res 2001; 11: 435-45.
3. Brown JE, Butow PN, Culjak G, Coates AS, Dunn SM. Psychosocial predictors of outcome: time to relapse and survival in patients with early stage melanoma. Br J Cancer 2000; 83: 1148-53.
4. Bucceri G. Depressive reactions to lung cancer are common and often followed by a poor outcome. Eur Respir J 1998; 11: 173-8.
5. Butow PN, Coates AS, Dunn SM. Psychosocial predictors of survival in metastatic melanoma. J Clin Oncol 1999; 17: 2256-63.
6. Chang VT, Thaler HT, Polyak TA, Kornblith AB, Lepore JM, Portenoy RK. Quality of life and survival. Cancer 1998; 83: 173-9.
7. Coates A, Gebski V, Signorini D, et al. Prognostic value of quality-of-life scores during chemotherapy for advanced breast cancer. J Clin Oncol 1992; 10: 1833-8.
8. Coates A, Thomson D, McLeod GRM, et al. Prognostic value of quality of life scores in a trial of chemotherapy with or without interferon in patients with metastatic melanoma. Eur J Cancer 1993; 29A: 1732-4.
9. Coates A, Gebski V. On the receiving end. VI. Which dimensions of quality-of-life scores carry prognostic information? Cancer Treat Rev 1996; 22 (Suppl A): S63-7.
10. Coates A, Porzsolt F, Osoba D. Quality of life in oncology practice: prognostic value of EORTC QLQ-C30 scores in patients with advanced malignancy. Eur J Cancer 1997; 33: 1025-30.
11. Coates AS, Hürny C, Peterson HF, et al. Quality-of-life scores predict outcome in metastatic but not early breast cancer. J Clin Oncol 2000; 18: 3768-74.
12. Kaasa S, Mastekaasa A, Lund E. Prognostic factors for patients with inoperable non-small cell lung cancer, limited disease. Radiother Oncol 1989; 15: 235-42.
13. Seidman A, Portenoy R, Yao T-J, et al. Quality of life in phase II trials: a study of methodological and predictive value in patients with advanced breast cancer treated with paclitaxel plus granulocyte colony-stimulating factor. J Natl Cancer Inst 1995; 87: 1316-22.
14. Tamburini M, Brunelli C, Rosso S, Ventafridda V. Prognostic value of quality of life scores in terminal cancer patients. J Pain Symptom Manage 1996; 1: 32-41.
15. Wisløff F, Hjort M. Health-related quality of life assessed before and during chemotherapy predicts for survival in multiple myeloma. Br J Haematol 1997; 97: 29-37.
16. Fawzy FI, Fawzy NW, Hyun CS, et al. Malignant melanoma. Effects of an early structured psychiatric intervention, coping, and affective state on recurrence and survival 6 years later. Arch Gen Psychiatry 1993; 9: 681-9.
17. Fawzy FI, Canada AL, Fawzy NW. Malignant melanoma: effects of a brief structured psychiatric intervention on survival and recurrence at 10-year follow-up. Arch Gen Psychiatry 2003; 60: 100-3.
18. Dalton SO, Boesen EH, Ross L, Schapiro IR, Johansen C. Mind and cancer: do psychological factors cause cancer? Eur J Cancer 2002; 38: 1313-23.
19. Brandberg Y, Månsson-Brahme E, Ringborg U, Sjödén PO. Psychological reactions in patients with malignant melanoma. Eur J Cancer 1995; 31A: 157-62.
20. Brandberg Y, Bergenmar M, Bolund C, et al. Information to patients with malignant melanoma: a randomized group study. Patient Ed Couns 1994; 23: 97-105.
21. Zigmond AS, Snaith RP. The Hospital Anxiety and Depression scale. Acta Psychiatr Scand 1983; 67: 361-70.
22. Herrmann C. International experiences with the Hospital Anxiety and Depression scale - a review of validation data and clinical results. J Psychosom Res 1997; 42: 17-41.
23. Herrmann C, Brand-Driehorst S, Kaminsky B, Leibing E, Staats H, Rüger U. Diagnostic groups and depressed moods as predictors of 22-month mortality in medical inpatients. Psychosom Med 1998; 60: 570-7.
24. Bjelland I, Dahl A, Tangen Haug T, Neckelmann D. The validity of the Hospital Anxiety and Depression scale: an updated literature review. J Psychosom Res 2002; 52: 69-77.
25. Brandberg Y, Bolund C, Sigurdardottir V, Sjödén PO, Sullivan M. Anxiety and depressive symptoms at different stages of malignant melanoma. Psycho-Oncology 1992; 1: 71-8.
26. Lisspers J, Nygren A, Söderman E. Hospital Anxiety and Depression scale (HAD): some psychometric data for a Swedish sample. Acta Psychiatr Scand 1997; 96: 281-6.
27. Maisey NR, Norman A, Watson M, Allen MJ, Hill ME, Cunningham D. Baseline quality of life predicts survival in patients with advanced colorectal cancer. Eur J Cancer 2002; 38: 1351-7.
28. Fawzy FI, Kemeny ME, Fawzy NW, et al. A structured psychiatric intervention for cancer patients. II. Changes over time in immunological measures. Arch Gen Psychiatry 1990; 8: 729-35.